Guardant Health (GH) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Voting matters and shareholder proposals
Election of two Class II director nominees: Ian Clark and Manuel Hidalgo Medina, both recommended by the board.
Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the year ending December 31, 2026.
Non-binding advisory vote to approve named executive officer compensation.
Non-binding advisory vote on the frequency of stockholder advisory votes regarding executive compensation, with 'Year' as the recommended frequency.
Other business may be addressed as appropriate during the meeting or any adjournment.
Board of directors and corporate governance
Board recommends the election of two Class II director nominees for continued governance oversight.
Executive compensation and say-on-pay
Advisory vote solicited to approve compensation for named executive officers.
Advisory vote on the frequency of future say-on-pay votes, with annual votes recommended.
Latest events from Guardant Health
- Record growth, new approvals, and guideline inclusion set stage for accelerated expansion.GH
Jefferies Global Healthcare Conference 20264 Jun 2026 - Rapid growth and innovation in cancer diagnostics, with Shield driving record adoption and revenue.GH
46th Annual William Blair Growth Stock Conference2 Jun 2026 - Q2 revenue up 31% year-over-year; 2025 guidance raised on strong growth and Shield FDA approval.GH
Q2 202529 May 2026 - Raised guidance on strong oncology and Shield growth, with AI and data driving future expansion.GH
Bank of America Global Healthcare Conference 202619 May 2026 - Revenue up 48% to $302M; guidance raised on strong oncology and screening growth.GH
Q1 20268 May 2026 - Record revenue growth, new product launches, and strong governance mark this year's proxy.GH
Proxy filing28 Apr 2026 - Quest partnership and CRC guideline updates drive growth, with Shield revenue set for strong gains.GH
Leerink Global Healthcare Conference 202626 Apr 2026 - Smart platform innovation and Shield’s multi-cancer expansion drive robust 2025 growth and 2026 outlook.GH
44th Annual J.P. Morgan Healthcare Conference22 Apr 2026 - 2025 revenue up 33% to $982M; 2026 outlook targets 27–30% growth and Shield expansion.GH
Q4 202511 Apr 2026